In conclusion, our study presents a modular approach to designing BH3 mimetics for AML, leveraging ncAAs and targeted motif engineering to achieve dual inhibition of MCL‐1 and BCL‐xL, effectively addressing Venetoclax‐associated resistance mechanisms. The gene discussed is BCL2L1; the disease is acute myeloid leukemia.